WebXYWAV NDA 212690. Page 2 of 10. I. EXECUTIVE SUMMARY. 1. Background. This memorandum responds to a consult request by the Division of Neurology Products 1 (DNP1) to evaluate the abuse potential of JZP-258 (proposed trade name: XYWAV) submitted by Jazz pharmaceuticals in NDA 212690. JZP-258 is an orally administered solution. The … WebXywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of cataplexy or excessive daytime sleepiness in patients …
Xywav: Side Effects, Cost, Uses, Dosage, and More
WebSponsored by. Chapter provides you with the most comprehensive Medicare guidance in America — at no cost to you. Here’s how it works: Call one of Chapter’s licensed Medicare experts at 800-251-6473. Compare every Medicare plan from every carrier. Save on average $1,100 per year on your coverage. Get Medicare help from an expert who cares. WebWebMD provides common contraindications for Xywav. Find out what health conditions may be a health risk when taken with Xywav ... Xywav Generic Name(s): sodium,calcium,mag,pot oxybate . Uses ... emily purses
Xywav (Calcium Magnesium Potassium and Sodium Oxybates)
WebJun 16, 2024 · Xywav is available only as a brand-name medication. It’s not currently available in generic form. A generic drug is an exact copy of the active drug in a brand … WebAug 6, 2024 · Jazz Pharmaceuticals’ XYWAV ™ (calcium, magnesium, potassium, and sodium oxybates) is the first US Food and Drug Administration (FDA) approved medicine indicated for the treatment of cataplexy and excessive daytime sleepiness (EDS) associated with narcolepsy in over 15 years.. It contains 92% less sodium than Xyrem ® (sodium … WebTrade Name: Xywav oral solution Generic or Proper Name: calcium, magnesium, potassium, and sodium oxybates Sponsor: Jazz Pharmaceuticals, Inc. Approval Date: July 21, 2024 Indication: provides for the use of Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, 0.5 g/mL, emily p walker ct